1. Home
  2. NXL vs BGI Comparison

NXL vs BGI Comparison

Compare NXL & BGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • BGI
  • Stock Information
  • Founded
  • NXL 2010
  • BGI 1879
  • Country
  • NXL United States
  • BGI Canada
  • Employees
  • NXL N/A
  • BGI N/A
  • Industry
  • NXL Medical Specialities
  • BGI
  • Sector
  • NXL Health Care
  • BGI
  • Exchange
  • NXL Nasdaq
  • BGI Nasdaq
  • Market Cap
  • NXL 14.0M
  • BGI 15.9M
  • IPO Year
  • NXL 2022
  • BGI 2005
  • Fundamental
  • Price
  • NXL $0.84
  • BGI $0.84
  • Analyst Decision
  • NXL Strong Buy
  • BGI
  • Analyst Count
  • NXL 1
  • BGI 0
  • Target Price
  • NXL $5.00
  • BGI N/A
  • AVG Volume (30 Days)
  • NXL 2.9M
  • BGI 201.0K
  • Earning Date
  • NXL 08-06-2025
  • BGI 07-25-2025
  • Dividend Yield
  • NXL N/A
  • BGI N/A
  • EPS Growth
  • NXL N/A
  • BGI N/A
  • EPS
  • NXL N/A
  • BGI N/A
  • Revenue
  • NXL $174,813.00
  • BGI $124,446,731.00
  • Revenue This Year
  • NXL $38.28
  • BGI N/A
  • Revenue Next Year
  • NXL $185.71
  • BGI N/A
  • P/E Ratio
  • NXL N/A
  • BGI N/A
  • Revenue Growth
  • NXL 16.42
  • BGI N/A
  • 52 Week Low
  • NXL $0.59
  • BGI $0.56
  • 52 Week High
  • NXL $4.49
  • BGI $2.95
  • Technical
  • Relative Strength Index (RSI)
  • NXL 45.15
  • BGI 65.04
  • Support Level
  • NXL $0.78
  • BGI $0.64
  • Resistance Level
  • NXL $0.99
  • BGI $1.07
  • Average True Range (ATR)
  • NXL 0.12
  • BGI 0.08
  • MACD
  • NXL 0.01
  • BGI 0.02
  • Stochastic Oscillator
  • NXL 25.40
  • BGI 46.53

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

Share on Social Networks: